Table 4 Disease status and drug use status of survival patients with IIM through using the MDAAT, HAQDI and MRS at the end of follow-up.
| Â | All | PM | DM | ADM | OM | JM |
|---|---|---|---|---|---|---|
No. of patients (%) | 156 | 37 | 80 | 9 | 24 | 6 |
MYOACT global disease activity, 10-cm VAS score = 0, n. (%) | 134(85.9) | 31(83.8) | 69(86.3) | 7(77.8) | 21(87.5) | 6(100.0) |
MYOACT global disease activity, 10-cm VAS score > 0, n. (%) | 22(14.1) | 6(16.2) | 11(13.8) | 2(22.2) | 3(12.5) | 0(0.0) |
MYOACT muscle disease activity, 10-cm VAS score > 0.2, n. (%) | 12(7.7) | 3(8.1) | 6(7.5) | 2(22.2) | 1(4.2) | 0(0.0) |
MYOACT, subscale VAS score > 0.2, no (%). | Â | Â | Â | Â | Â | Â |
   Constitutional | 13(8.3) | 1(2.7) | 9(11.3) | 1(11.1) | 2(8.3) | 0(0.0) |
   Cutaneous | 11(7.1) | 1(2.7) | 6(7.5) | 2(22.2) | 2(8.3) | 0(0.0) |
   Skeletal | 7(4.5) | 4(10.8) | 2(2.5) | 0(0.0) | 1(4.2) | 0(0.0) |
   Gastrointestinal | 0(0.0) | 0(0.0) | 0(0.0) | 0(0.0) | 0(0.0) | 0(0.0) |
   Pulmonary | 15(9.6) | 6(16.2) | 6(7.5) | 2(22.2) | 1(4.2) | 0(0.0) |
   Cardiac | 2(1.3) | 2(5.4) | 0(0.0) | 0(0.0) | 0(0.0) | 0(0.0) |
Patients with HAQDI score = 0, n. (%) | 130(83.3) | 33(89.2) | 64(80.0) | 8(88.9) | 17(70.8) | 6(100.0) |
Patients with HAQDI score > 0, n. (%) | 26(16.7) | 4(10.8) | 15(18.8) | 1(11.1) | 6(25.0) | 0(0.0) |
Patients with M RS = 0, n. (%) | 131(84.0) | 34(91.9) | 66(82.5) | 9(100) | 16(66.7) | 6(100.0) |
Patients with MRS ≥1, n. (%) | 25(16.0) | 3(8.1) | 14(17.5) | 0(0.0) | 8(33.3) | 0(0.0) |
Medication | Â | Â | Â | Â | Â | Â |
   Off all drugs | 29(18.6) | 9(24.3) | 16(20.0) | 1(11.1) | 3(12.5) | 0(0.0) |
   Corticosteroid, 0-5 mg/d, n. (%) | 73(46.8) | 16(43.2) | 37(46.3) | 4(44.4) | 12(50.0) | 4(66.7) |
   Corticosteroid, 5-10 mg/d, n. (%) | 34(21.8) | 8(21.6) | 17(21.3) | 2(22.2) | 5(20.8) | 2(33.3) |
   Corticosteroid, 10-15 mg/d, n. (%) | 9(5.8) | 1(2.7) | 6(7.5) | 0(0.0) | 2(8.3) | 0(0.0) |
   Corticosteroid, > 15 mg/d, n. (%) | 11(7.1) | 3(8.1) | 4(5.0) | 2(22.2) | 2(8.3) | 0(0.0) |
   Second-line agents†, n. (%) | 30(19.2) | 10(27.0) | 14(17.5) | 1(11.1) | 3(12.5) | 2(33.3) |